Andrew McLoughlin

A breathomics database to identify, contextualise and validate biomarkers of respiratory conditions

Breath-based biomarker development relies on advanced technology to collect and analyse volatile organic compounds (VOCs). Traditionally, untargetted GC-MS analysis is prefered for biomarker discover…

High-quality identification of volatile organic compounds (VOCs) originating from breath

Objectives: To build a reliable breath collection and analysis method that can produce a comprehensive list of known VOCs in the breath of a heterogeneous human population.

A Randomized Pragmatic Trial of Changing to and Stepping Down Fluticasone/Formoterol in Asthma

In a randomized controlled, pragmatic, open-label trial, 225 well-controlled patients with asthma were randomized (1:2) to maintain high-dose fluticasone propionate/salmeterol xinafoate (FP/SAL,...

Age at menarche and risks of all-cause and cardiovascular death: a systematic review and meta-analysis

We conducted a systematic review and meta-analysis to investigate the associations between menarcheal age and all-cause and cardiovascular death. Medline, Embase, Scopus, and Web of Knowledge were...

Introducing the Breath Biopsy® VOC Atlas: A List of Microbiome-Associated VOCs for Breath-Based Biomarker Discovery

Volatile organic compound (VOC) biomarkers in exhaled breath offer a promising solution to safe, non-invasive diagnostics in multiple disease settings. Some of these VOCs are linked to the gastrointe…

Breath Biopsy® Technology

Many breath-based studies have been performed in several disease conditions, but there are few validated breath-based biomarkers currently in clinical use. The complex and unknown composition of the …

Introducing the VOC Atlas: A List of Microbiome-Associated VOCs for Breath-Based Biomarker Discovery

The gastrointestinal (GI) microbiome plays a crucial role in digestive health. Apart from providing colonization resistance to pathogens, it produces a myriad of metabolites that function to enforce …

Analyzing Metabolic Responses to a Standardized Meal Challenge Using Exhaled Breath

Conclusion: This study underscores the utility of breath analysis in advancing our understanding of metabolic responses to dietary stimuli. The platform effectively identified established nutrition a…

Optimized tools for the reliable sampling and analysis of breath for research and clinical use

Analysis of biological samples such as blood, urine, and fecal matter is essential in both clinical research and clinical practice. Informative compounds within these sampling mediums are quantified …

Introducing Breath Biopsy® VOC Atlas: A List of Known Breath VOCS for Breath-based Biomarker Discovery

The Atlas study was designed to provide a comprehensive catalogue of VOCs identified on exhaled human breath, the Breath Biopsy VOC Atlas, to support development of breath VOC biomarkers and diagnost…

Optimized breath analysis: customized analytical methods and enhanced workflow for broader detection of VOCs

Breath Volatile organic compounds (VOCs) are promising biomarkers for clinical purposes due to their unique properties. Translation of VOC biomarkers into the clinic depends on identification and val…

Progress and challenges of developing volatile metabolites from exhaled breath as a biomarker platform

The multitude of metabolites generated by physiological processes in the body can serve as valuable biomarkers for many clinical purposes. They can provide a window into relevant metabolic pathways f…

Establishing breath as a biomarker platform—take home messages from the Breath Biopsy Conference 2023

The annual Breath Biopsy Conference hosted by Owlstone Medical gathers together the leading experts, early career researchers, and physicians working with breath as a biomarker platform for clinical …

Determinants of increase FeNO in individuals with suspected asthma

Airway inflammation is the fundamental mechanism in asthma and can be measured non-invasively by means of fractional exhaled nitric oxide (FeNO). Both, The National Institute for Health and Care...

Pragmatic trial stepping down Flutiform® in patients maintained on high dose ICS

Global Initiative for Asthma (GINA) guidelines recommend a gradual step-down of asthma therapy if asthma has been well-controlled for at least 3 months. In real life, however, many well-controlled...

Pragmatic trial comparing continuing Seretide® MDI with changing to Flutiform® in asthma

Selecting the most appropriate asthma therapy for individual patients can be challenging owing to limited data on real-life effectiveness of inhaled corticosteroid (ICS)/long-acting beta2-agonist...

Meeting abstracts from the Respiratory Effectiveness Group 2015 Winter Summit; databases and registries around the world: maximizing the yield